Shocked to find out yesterday that NICE have rejected. Alectinib as 1st line treatment!!!!
Crazy decision as it crosses the BBB whereas Crixotinib rarely does, has fewer adverse side effects allowing people to continue a completely normal life. This drug is for people who are ALK + and tend to be below the age of 50. My daughter is 30 and I know Of people much younger.
This drug enabled this amazing group of people to carry on working/ studying and contributing to society.
This drug also had a median progression free time of 26 months. Crixotinib has about a year.
I know people in USA. Where it was granted approval in 2016 who are going into their fifth year on this.( They were on clinical trials)
My daughter is very lucky that she gained access too this drug 1st line through EAMS.
Oncologists obviously realise it's the best 1st line treatment or she would have been put on Crizotinib which is approved!!!
Breaks my heart for newly diagnosed AlKIES denied this wonder drug